Armstrong Amy E, Smyth Eileen, Helenowski Irene B, Tse William T, Duerst Reggie E, Schneiderman Jennifer, Kletzel Morris, Chaudhury Sonali
*Division of Hematology/Oncology/Stem Cell Transplant, Ann & Robert H. Lurie Children's Hospital of Chicago †Stem Cell Transplantation, Ann & Robert H. Lurie Children's Hospital of Chicago §Department of Pediatrics, Northwestern University Feinberg School of Medicine ‡Department of Preventive Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL.
J Pediatr Hematol Oncol. 2017 Jan;39(1):26-32. doi: 10.1097/MPH.0000000000000690.
Current practice for selecting donor units for umbilical cord blood transplant (UCBT) involves matching at HLA-A and HLA-B by low-resolution typing and the HLA-DRB1 allele by high-resolution (HR) typing. We retrospectively studied the impact of HR allele matching at HLA-A, HLA-B, HLA-C, and HLA-DRB1 on transplant-related outcomes in 60 single-unit UCBTs in pediatric patients with malignant and nonmalignant conditions. Five-year overall survival of our cohort was 71% (95% confidence interval, 58-81); 27% experienced primary graft failure. Applying HR typing, donor-recipient mismatch variability increased ranging from 1/8 to 8/8, however, no impact on primary graft failure, graft-versus-host disease or posttransplant infection was observed. UCBTs with ≥6/8 HR matches did have a better overall survival (P=0.04) and decreased transplant-related mortality (P=0.02) compared with <6/8 HR matches. Using standard HLA typing, we showed an increased incidence of acute graft-versus-host disease (grade II to IV) and decreased transplant-related mortality in comparing the matched (6/6) versus ≤5/6 group (P=0.05 and 0.05, respectively). These data support the use of current guidelines for umbilical cord blood selection and encourage utilization of HR typing to select umbilical cord blood units matched at ≥6/8 especially when appropriate ≥5/6 units are available.
目前选择脐带血移植(UCBT)供体单位的做法包括通过低分辨率分型匹配HLA - A和HLA - B,以及通过高分辨率(HR)分型匹配HLA - DRB1等位基因。我们回顾性研究了HLA - A、HLA - B、HLA - C和HLA - DRB1的HR等位基因匹配对60例患有恶性和非恶性疾病的儿科患者进行单单位UCBT时移植相关结局的影响。我们队列的5年总生存率为71%(95%置信区间,58 - 81);27%经历了原发性移植物失败。应用HR分型后,供体 - 受体错配变异性增加,范围从1/8到8/8,然而,未观察到对原发性移植物失败、移植物抗宿主病或移植后感染有影响。与HR匹配<6/8的情况相比,HR匹配≥6/8的UCBT确实有更好的总生存率(P = 0.04)和降低的移植相关死亡率(P = 0.02)。使用标准HLA分型,我们发现在比较匹配(6/6)组与≤5/6组时,急性移植物抗宿主病(II至IV级)的发生率增加,移植相关死亡率降低(分别为P = 0.05和0.05)。这些数据支持使用当前的脐带血选择指南,并鼓励利用HR分型来选择HR匹配≥6/8的脐带血单位,特别是在有合适的≥5/6单位可用时。